3E Acquires Workplace Safety Provider, Quick-FDS
3.4.2024 10:00:00 EEST | Business Wire | Press release
3E, the leading global provider of intelligent compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, has completed its previously announced acquisition of Quick-FDS, the leading provider of workplace safety solutions in France. The acquisition of Quick-FDS from WEKA Group further expands 3E’s presence in Europe and establishes a leading position in the French market in particular.
Quick-FDS partners with both global manufacturers and downstream users of chemical products, providing mission-critical solutions that enable improved regulatory compliance and workplace safety. The Company has developed a highly specialized knowledge base and resource library of Safety Data Sheets (“SDS”), allowing many of the world’s largest companies to comply with both local and global regulatory pressures.
“We are thrilled to welcome Quick-FDS’ team, clients and partners into the broader 3E organization. Expanding in the French market has been a high priority for 3E and we are excited to accelerate our growth in the country through the combination of two industry-leading businesses,” said Greg Gartland, Chief Executive Officer of 3E. “This combination further solidifies 3E as the global leader in SDS management, empowering clients to improve chemical and workplace safety in a world with increasingly complex regulations.”
Deep knowledge and understanding of continuously evolving regulations have become critical for companies in and adjacent to the chemical industry. REACH regulations in the EU require all suppliers of chemicals to provide a unique Safety Data Sheet for each chemical substance to their customers. Quick-FDS’ market-leading solution enables compliance with REACH and a variety of other EU regulations, allowing customers to execute on their strategic goals while adhering to increasingly stringent requirements.
Robin Dualé, Managing Director of WEKA Group in France, said “This combination represents a significant milestone in the EHS&S industry, bringing together two of the most sophisticated providers of SDS management, workplace safety, and product stewardship solutions in Europe. The breadth of solutions that the combined company will be able to provide to clients is unparalleled, allowing for more informed decisions while reducing regulatory risks consistently, efficiently, and confidently.”
“This combination is highly strategic as 3E continues to expand its presence in Europe and across the globe,” added JP O'Sullivan, Chief Operating Officer at 3E. "With the combined strengths and capabilities of both 3E and Quick-FDS, we remain deeply committed to offering safety and compliance solutions to our clients and will be able to provide greater value and expertise as we serve an expanding global customer base."
3E has been active in strategic acquisition efforts since its separation from Verisk, having acquired Toxnot, Chemycal, ChemChain, and now Quick-FDS since March of 2022.
Shearman & Sterling LLP and Proskauer Rose LLP serve as the legal advisors to 3E. WEKA Group and Quick-FDS are advised by Carlsquare (M&A) and Astura (Legal).
About Quick-FDS
Quick-FDS provides digital workflow solutions related to Safety Data Sheet management to help manufacturers and end-users along the full supply chain for chemical products comply with global regulations, including European REACH. Quick-FDS’ historical success is driven by tight integration with compliance-related workflows throughout the chemical and specialty materials sector. Global chemical manufacturers, distributors, and wholesalers strongly endorse Quick-FDS as a true partner within their broader regulatory strategy.
About 3E
For more than 35 years the world’s leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world’s largest chemical manufacturers, retailers and pharmaceutical companies. Learn more at www.3Eco.com
About WEKA Group
WEKA Group is a diversified group of media companies and a leading provider of specialist information and advanced education with 15 operational companies in Germany, Austria, and France. WEKA Group’s media-neutral content is offered in all common formats and reaches highly diversified niche markets across all industries. WEKA Group is headquartered in Kissing, Germany, and employs approximately 1,000 employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328295790/en/
Contact information
Media:
Maria Rutland
3E
maria.rutland@3eco.com
+1.760.987.5152
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom